Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Intraoperative Detection of Residual Cancer in Breast Cancer

ClinicalTrials.gov ID: NCT03321929

Public ClinicalTrials.gov record NCT03321929. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Feasibility Study Phase C: Expansion Into Multiple Institutions for Training in the Use of the LUM Imaging System for Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Subjects With Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a non-randomized, open-label, multi-site study to collect safety and efficacy data on an intraoperative imaging system, the LUM Imaging System (LUM015 imaging agent in conjunction with the LUM imaging device), in identifying residual cancer in the tumor bed of female breast cancer patients. During the study, study physicians and clinical staff will complete hands-on training in anticipation of the upcoming pivotal study. Site-specific or user-specific issues related to the use of the device will be identified and addressed. Additionally, the data collected in the study will be used to continue training the tumor detection algorithm of the device. In this study, patients will be injected with LUM015 prior to surgery. The study physicians will perform lumpectomy procedures according to his or her institution's standard of care practice. After the main specimen removal is completed, the study physician will use the LUM Imaging Device to image the tumor bed. Therapeutic shaves will be removed based on the recommendation of the LUM Imaging System. Patients will be followed until their first standard of care post-operative follow-up visit.

Study identification

NCT ID
NCT03321929
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Lumicell, Inc.
Industry
Enrollment
234 participants

Conditions and interventions

Conditions

Interventions

Combination Product

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 6, 2018 (Actual)
Primary completion
Apr 10, 2020 (Actual)
Completion
Apr 10, 2020 (Actual)
Last update posted
May 1, 2023

2018 – 2020

United States locations

U.S. sites
16
U.S. states
11
U.S. cities
16
Facility City State ZIP Site status
University of South Alabama Mobile Alabama 36604 —
Stanford University Medical Center Palo Alto California 94304 —
Yale University School of Medicine New Haven Connecticut 06511 —
Comprehensive Breast Care Center Clearwater Florida 33756 —
Baptist MD Anderson Cancer Physicians Jacksonville Florida 32207 —
Massachusetts General Hospital Boston Massachusetts 02114 —
Lahey Hospital and Medical Center Burlington Massachusetts 01805 —
Beaumont Royal Oak Royal Oak Michigan 48073 —
Beaumont Troy Troy Michigan 48098 —
Duke University Medical Center Durham North Carolina 27710 —
Novant Health Winston-Salem North Carolina 27103 —
Cleveland Clinic Cleveland Ohio 44195 —
Penn State Hershey Medical Center Hershey Pennsylvania 17033 —
Dallas Breast Center Dallas Texas 75231 —
MD Anderson Cancer Center Houston Texas 77030 —
Franciscan Breast Surgery Tacoma Washington 98405 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03321929, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 1, 2023 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03321929 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →